LYNK Pharmaceuticals is based in Hangzhou, China. It has raised $50M in total funding. Latest round: Series B.
LYNK Pharmaceuticals is based in Hangzhou, China. LYNK Pharmaceuticals has raised $50M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series B announced in August 2021. The round record for LYNK Pharmaceuticals runs through 2021; nothing later has been disclosed. Investors on record include Lilly Asia Ventures, New Alliance Capital, Hangzhou HEDA Biological Medicine Venture Capital Partnersh…, Legend Capital, Med-Fine Capital. 5 distinct backers are named across the disclosed rounds.
Every LYNK Pharmaceuticals figure above comes from filings and announced rounds in the StartupFundraising company database and is revised as new rounds are recorded. The lists below compare companies in Hangzhou at a similar stage.
Company funding database · Investor directory · Founder database · Mega-rounds 2026